| Literature DB >> 35070971 |
Yu-Mei Zhang1, Guan-Zhong Gong2, Qing-Tao Qiu2, Yun-Wei Han1, He-Ming Lu3, Yong Yin1,2.
Abstract
Nasopharyngeal carcinoma (NPC) is a malignant tumor of the head and neck. The primary clinical manifestations are nasal congestion, blood-stained nasal discharge, headache, and hearing loss. It occurs frequently in Southeast Asia, North Africa, and especially in southern China. Radiotherapy is the main treatment, and currently, imaging examinations used for the diagnosis, treatment, and prognosis of NPC include computed tomography (CT), magnetic resonance imaging (MRI), positron emission tomography (PET)-CT, and PET-MRI. These methods play an important role in target delineation, radiotherapy planning design, dose evaluation, and outcome prediction. However, the anatomical and metabolic information obtained at the macro level of images may not meet the increasing accuracy required for radiotherapy. As a technology used for mining deep image information, radiomics can provide further information for the diagnosis and treatment of NPC and promote individualized precision radiotherapy in the future. This paper reviews the application of radiomics in the diagnosis and treatment of nasopharyngeal carcinoma.Entities:
Keywords: computerized tomography; magnetic resonance imaging; nasopharyngeal carcinoma; positron emission computed tomography; radiomics
Year: 2022 PMID: 35070971 PMCID: PMC8766636 DOI: 10.3389/fonc.2021.767134
Source DB: PubMed Journal: Front Oncol ISSN: 2234-943X Impact factor: 6.244
Figure 1Flow chart of radiomics.
Data of relevant models in references.
| Purpose | Authors | Imaging | Application | Method/model | Results | |
|---|---|---|---|---|---|---|
| Diagnosis | Diagnosis | Zhu et al. ( | MRI | staging | support vector machine classifier | C-index : training&validation group : 0.827&0.814(based on model), 0.815&0.803(based on T), 0.842&0.756(based on TNM) |
| Feng et al. ( | PET-MRI | staging | logistic regression models | AUC: training group:0.84(PET),0.85(T2-weighted); validation group:0.82(PET),0.83(T2-weighted) | ||
| Differential diagnosis | Zhong et al. ( | MRI | cervical spine osteoradionecrosis and bone metastasis | nomogram model | AUC: training group : 0.725 ; validation group:0.720 | |
| Du et al. ( | PET-CT | recurrence and inflammation | 7 types of machine learning classifiers | optimal combination of feature selection and machine learning methods | ||
| Treatment | ||||||
| Treatment response prediction | Yu et al. ( | MRI | pretreatment prediction of adaptive radiation | logistic regression model | AUC: training group: 0.962(CET1-w), 0.895(T2-weighted),0.984(joint T1-T2); validation group:0.852(CET1-w), 0.750(T2-weighted),0.930(joint T1-T2) | |
| Zhao et al. ( | MRI | predict the response to induction chemotherapy and survival | support vector machine, radiomics nomogram | C-index : training&validation group:0.952&0.863(radiomics signature with clinical data),0.708&0.549(clinical nomogram alone) | ||
| Piao et al. ( | MRI | early response of neoadjuvant chemotherapy | Cox regression model | AUC: 0.905(combined), 0.804(ClusterShade_angle135_offset 4)、0.762(Correlation_AllDirection_offshel_SD) | ||
| Prognosis prediction | ||||||
| Ouyang et al. ( | MRI | radiomics signature as a prognostic biomarker | multivariate Cox proportional hazards model | Hazard ratio (HR): 5.14(discovery set), 7.28(validation set) | ||
| Shen et al. ( | MRI | predicting progression-free survival (PFS) | Cox model | Model 5 incorporating radiomics, overall stage, and EBV DNA yielded the highest C-index for predicting PFS (training cohorts: 0.805, validation cohorts: 0.874) | ||
| Ming et al. ( | MRI | disease free-survival (DFS), overall survival (OS), distant metastasis-free survival (DMFS) | Cox regression model | C-index : validation group: 0.751(DFS)、0.845(OS)、0、643(DMFS) | ||
| Yang et al. ( | MRI | PFS | Nomogram | C-index: validation group: 0.811(including three factors),0.613(just TNM) | ||
| Lv et al. ( | PET-CT | PFS | Cox regression model | C-index: validation group: 0.67–0.73 | ||
| Xu et al. ( | PET-CT | PFS | Cox’s proportional hazard model | C-index: 0.69(S3), 0.58(whole tumor) | ||
| Zhang et al. ( | MRI | distant metastasis | logistic regression model | AUC: training&validation groups: 0.827&0.792 | ||
| Zhang et al. ( | MRI | local recurrence | Cox proportional hazard model, nomogram | C-index: validation groups: 0.74(radiomic features and multiple clinical variables) | ||
| Raghavan et al. ( | MRI | recurrence | multivariate logistic regression model, Cox proportional model | local recurrence model: 0.82(AUC), 0.73(sensitivity), and 0.74(specificity);distant metastasis model: 0.92(AUC), 0.79(sensitivity), and 0.84(specificity) | ||
| Zhang et al. ( | MRI | optimal machine-learning methods for the radiomics-based prediction of local failure and distant failure | machine-learning methods | optimal combination random forest + random forest AUC:0.8464 ± 0.0069 | ||
| Li et al. ( | MRI | recurrence patterns | machine-learning methods,support vector machine (SVM) models | NPCs with in-field recurrences (NPC-IFR) and NPCs with non-progression disease (NPC-NPD) could be differentiated (AUCs: 0.727–0.835). | ||
| Prediction of side effects | Liu et al. ( | CT | prediction of Acute Xerostomia | support vector regression | accuracy: 0.9220, sensitivity: 100% | |
| Zhang et al. ( | MRI | radiation-Induced Brain Injury | Random forest method | AUC: validation groups: 0.830 (model1), 0.773 (model2), and 0.716(model3) | ||
| Stability characteristic study | Liang et al. ( | MRI | Moddicom (v. 0.51),Pyradiomics (v. 2.1.2) | Spearman’s rank correlation | Selection of stable features of the disease is key. | |
| Lu et al. ( | PET-CT | different contrast agents | ICC | features extracted from [11C] choline are more stable than those extracted from the [18F]-FDG contrast agent. | ||
| Yang et al. ( | PET-MRI | robust radiomic features | intraclass correlation coefficient (ICC) and spearman correlation coefficient | voxel size: 0.5 × 0.5 × 1.0 mm3; normalized grey level:64 and 128 | ||
| Lv et al. ( | PET-CT | robustness | ICC | poor absolute-scale robustness still has good diagnostic performance. |